|A risk score to predict bleeding in patients with acute coronary syndromes.|
|PMID: 20513595 Owner: NLM Status: MEDLINE|
|OBJECTIVES: The aim of this study was to develop a practical risk score to predict the risk and implications of major bleeding in acute coronary syndromes (ACS). BACKGROUND: Hemorrhagic complications have been strongly linked with subsequent mortality in patients with ACS. METHODS: A total of 17,421 patients with ACS (including non-ST-segment elevation myocardial infarction [MI], ST-segment elevation MI, and biomarker negative ACS) were studied in the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) and the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trials. An integer risk score for major bleeding within 30 days was developed from a multivariable logistic regression model. RESULTS: Non-coronary artery bypass graft surgery (CABG)-related major bleeding within 30 days occurred in 744 patients (7.3%) and had 6 independent baseline predictors (female sex, advanced age, elevated serum creatinine and white blood cell count, anemia, non-ST-segment elevation MI, or ST-segment elevation MI) and 1 treatment-related variable (use of heparin + a glycoprotein IIb/IIIa inhibitor rather than bivalirudin alone) (model c-statistic = 0.74). The integer risk score differentiated patients with a 30-day rate of non-CABG-related major bleeding ranging from 1% to over 40%. In a time-updated covariate-adjusted Cox proportional hazards regression model, major bleeding was an independent predictor of a 3.2-fold increase in mortality. The link to mortality risk was strongest for non-CABG-related Thrombolysis In Myocardial Infarction (TIMI)-defined major bleeding followed by non-TIMI major bleeding with or without blood transfusions, whereas isolated large hematomas and CABG-related bleeding were not significantly associated with subsequent mortality. CONCLUSIONS: Patients with ACS have marked variation in their risk of major bleeding. A simple risk score based on 6 baseline measures plus anticoagulation regimen identifies patients at increased risk for non-CABG-related bleeding and subsequent 1-year mortality, for whom appropriate treatment strategies can be implemented.|
|Roxana Mehran; Stuart J Pocock; Eugenia Nikolsky; Tim Clayton; George D Dangas; Ajay J Kirtane; Helen Parise; Martin Fahy; Steven V Manoukian; Frederick Feit; Magnus E Ohman; Bernard Witzenbichler; Giulio Guagliumi; Alexandra J Lansky; Gregg W Stone|
Related Documents :
|15179105 - Heart rate variability decreased by coronary artery surgery has no prognostic value.
23863255 - Usefulness of combined bedside lung ultrasound and echocardiography to assess weaning f...
12645705 - Coronary reoperations: recurrence of angina and clinical outcome with and without cardi...
25069885 - Electrocardiographic characteristics of the right ventricle following hemodynamic impro...
10214475 - The combination of risk factors for sudden death in a resuscitated elderly patient with...
18988915 - Sonographic evaluation of hemorrhagic transformation and arterial recanalization in acu...
|Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't|
|Title: Journal of the American College of Cardiology Volume: 55 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2010 Jun|
|Created Date: 2010-06-01 Completed Date: 2010-07-01 Revised Date: -|
Medline Journal Info:
|Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States|
|Languages: eng Pagination: 2556-66 Citation Subset: AIM; IM|
|Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.|
|Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Acute Coronary Syndrome
Aged, 80 and over
Angioplasty, Transluminal, Percutaneous Coronary / methods
Cause of Death*
Coronary Artery Bypass / methods
Fibrinolytic Agents / adverse effects*, therapeutic use
Hemorrhage / chemically induced*, mortality*
Heparin / adverse effects, therapeutic use
Hospital Mortality / trends
Platelet Aggregation Inhibitors / adverse effects*, therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / adverse effects, therapeutic use
Predictive Value of Tests
Proportional Hazards Models
Severity of Illness Index
|0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 9005-49-6/Heparin|
|J Am Coll Cardiol. 2010 Jun 8;55(23):2567-9
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of the Extent of Coronary Artery Disease on Outcomes After Revascularization for Unprotected ...
Next Document: Active Cascade Screening in Primary Inherited Arrhythmia Syndromes Does It Lead to Prophylactic Trea...